Table 2.
20 most commonly selected cancer medicines by 948 oncologists
|
Overall |
Low-income and lower-middle-income countries |
Upper-middle-income countries |
High-income countries |
|||||
|---|---|---|---|---|---|---|---|---|
| Top 20 drugs | Number of respondents (%) | Top 20 drugs | Number of respondents (%) | Top 20 drugs | Number of respondents (%) | Top 20 drugs | Number of respondents (%) | |
| 1 | Doxorubicin | 499 (53%) | Doxorubicin | 105 (64%) | Doxorubicin | 94 (57%) | Pembrolizumab* | 311 (50%) |
| 2 | Cisplatin | 470 (50%) | Cisplatin | 91 (55%) | Pembrolizumab* | 86 (52%) | Doxorubicin | 300 (49%) |
| 3 | Paclitaxel | 423 (45%) | Cyclophosphamide | 90 (55%) | Trastuzumab | 84 (51%) | Cisplatin | 300 (49%) |
| 4 | Pembrolizumab | 414 (44%) | Carboplatin | 84 (51%) | Cisplatin | 79 (48%) | 5-fluorouracil | 277 (45%) |
| 5 | Trastuzumab | 402 (42%) | Capecitabine | 80 (48%) | Carboplatin | 72 (44%) | Paclitaxel | 276 (45%) |
| 6 | Carboplatin | 390 (41%) | Paclitaxel | 79 (48%) | Paclitaxel | 68 (41%) | Trastuzumab | 275 (44%) |
| 7 | 5-fluorouracil | 386 (41%) | Docetaxel | 56 (34%) | Tamoxifen | 67 (41%) | Carboplatin | 234 (38%) |
| 8 | Tamoxifen | 345 (36%) | Tamoxifen | 50 (30%) | Capecitabine | 64 (39%) | Tamoxifen | 228 (37%) |
| 9 | Capecitabine | 329 (35%) | 5-fluorouracil | 49 (30%) | 5-fluorouracil | 60 (36%) | Capecitabine | 185 (30%) |
| 10 | Cyclophosphamide | 318 (34%) | Imatinib | 45 (27%) | Docetaxel | 57 (35%) | Oxaliplatin | 184 (30%) |
| 11 | Docetaxel | 296 (31%) | Gemcitabine | 45 (27%) | Cyclophosphamide | 51 (31%) | Docetaxel | 183 (30%) |
| 12 | Oxaliplatin | 269 (28%) | Trastuzumab | 43 (26%) | Oxaliplatin | 48 (29%) | Dexamethasone | 182 (29%) |
| 13 | Dexamethasone | 248 (26%) | Dexamethasone | 41 (25%) | Abiraterone | 41 (25%) | Cyclophosphamide | 177 (29%) |
| 14 | Nivolumab | 205 (22%) | Methotrexate | 40 (24%) | Anastrozole | 31 (19%) | Nivolumab | 173 (28%) |
| 15 | Rituximab | 203 (21%) | Vincristine | 40 (24%) | Osimertinib† | 29 (18%) | Rituximab | 146 (24%) |
| 16 | Imatinib | 184 (19%) | Oxaliplatin | 37 (22%) | Imatinib | 28 (17%) | Osimertinib† | 112 (18%) |
| 17 | Gemcitabine | 180 (19%) | Etoposide | 36 (22%) | Goserelin | 27 (16%) | Imatinib | 111 (18%) |
| 18 | Etoposide | 170 (18%) | Rituximab | 35 (21%) | Gemcitabine | 26 (16%) | Letrozole* | 111 (18%) |
| 19 | Osimertinib† | 157 (17%) | Bortezomib | 28 (17%) | Dexamethasone | 25 (15%) | Gemcitabine | 109 (18%) |
| 20 | Letrozole* | 143 (15%) | Gefitinib | 25 (15%) | Etoposide | 25 (15%) | Etoposide | 109 (18%) |
Data are n (%). Medicines listed are those selected by oncologists in response to the primary study question. Overall results are shown for all respondents in addition to rank order lists for three different World Bank economic classifications based on respondents' country of practice.
*
Valid substitution for a listed WHO Essential Medicines List (EML) medication based on identical drug class or mechanism.
†
Not included on the current WHO EML.